Lumida
/ABBV
⌘K
AbbVie Inc

AbbVie Inc

ABBV
$257.12USD+0.83%+2.12 today

MARKET CAP

454.4B

P/E (TTM)

126.7x

FWD P/E

DAY RANGE

$254 – $260

52W RANGE

$191
$267

AI Summary

Stalk
NeutralLow
  • Q2 2026 net revenues of $17B (+10.2% YoY) fueled by Skyrizi and Renvoke.
  • Adjusted EPS of $3.65 beat guidance; full-year revenue guide raised to $67.6B.
  • Humira revenues set to decline over $4B in 2026 due to biosimilars.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$56.2B$58.1B$54.3B$56.3B$61.2B
YoY %+22.7%+3.3%-6.4%+3.7%+8.6%
P / Sales4.3x5.0x5.2x5.6x6.6x
EV / Sales6.4x6.9x7.3x7.8x8.8x
Gross Profit, Adj.$38.8B$40.6B$33.9B$39.4B$43.0B
YoY %+27.4%+4.9%-16.6%+16.3%+8.9%
Margin %69.0%70.0%62.4%70.0%70.2%
EV / Gross Profit9.3x9.9x11.6x11.2x12.5x
EBITDA, Adj.$27.6B$27.3B$22.1B$20.3B$28.0B
YoY %+43.5%-1.0%-19.2%-8.1%+38.1%
Margin %49.1%47.0%40.6%36.0%45.8%
EV / EBITDA13.1x14.7x17.9x21.8x19.2x
EBIT$17.9B$18.1B$12.6B$9.1B$14.8B
YoY %+57.7%+1.1%-30.6%-27.4%+62.5%
Margin %31.9%31.2%23.2%16.2%24.3%
EV / EBIT20.2x22.1x31.4x48.3x36.2x
Net Income$11.5B$11.8B$4.8B$4.2B$4.2B
YoY %+151.7%+3.2%-59.3%-12.1%-1.2%
Net Margin20.4%20.4%8.9%7.5%6.8%
EPS (GAAP)$6.45$6.63$2.72$2.39$2.36
YoY %+137.1%+2.8%-59.0%-12.1%-1.3%